Articles Vol. 67 No. 9 25/09/2026

MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF PATIENTS UNDERGOING PROSTATIC ARTERY EMBOLIZATION FOR BENIGN PROSTATIC HYPERPLASIA AT HANOI MEDICAL UNIVERSITY HOSPITAL

Tran Van Tuan, Nguyen Ngoc Cuong, Phan Hoang Giang
DOI: 10.52163/yhc.v67i9.6748
18 Views
0 Downloads
Abstract

Objective: Describe the magnetic resonance imaging (MRI) characteristics of patients with benign prostatic hyperplasia (BPH) before undergoing prostatic artery embolization (PAE) at Hanoi Medical University Hospital.

Materials and Methods: This retrospective, cross-sectional study with longitudinal follow-up included 61 patients with BPH who underwent PAE at Hanoi Medical University Hospital between March 2024 and December 2025. MRI findings were analyzed according to the Wasserman classification, intravesical prostatic protrusion (IPP) grade, and their associations with clinical symptoms..

Results: The mean age of patients was 71.1 ± 9.3 years. The most common symptoms were dysuria (85.2%) and nocturia (67.2%). Among 61 patients, type 3 according to the Wasserman classification was the most prevalent (45.9%), followed by type 1 (24.7%). Grade III IPP (>10 mm) was observed in 47.6% of patients. The prevalence of overactive bladder (OAB) tended to be higher in type 5 (77.8%) compared to other types; however, the difference was not statistically significant (p = 0.149). There was a statistically significant difference in pre-treatment IPSS among groups (p = 0.040), with higher scores observed in type 2 (24.3 ± 4.5), type 3 (25.2 ± 5.5), and type 5 (23.6 ± 4.2) compared to type 1 (19.3 ± 7.8). Post-treatment IPSS decreased in all groups, with no statistically significant difference between types (p = 0.280).

Conclusion: MRI is a valuable imaging modality for the preprocedural assessment of benign prostatic hyperplasia (BPH), enabling morphological classification according to the Wasserman system and evaluation of intravesical prostatic protrusion (IPP). These imaging features are associated with pre-treatment symptom severity and provide useful information for patient evaluation prior to prostate artery embolization.

Keywords
Benign prostatic hyperplasia; Wasserman classification; overactive bladder
References
[1]
1. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol IJU J Urol Soc India. 2014;30(2):170-176. doi:10.4103/0970-1591.126900 Google Scholar
[2]
2. Wasserman NF, Spilseth B, Golzarian J, Metzger GJ. Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies. AJR Am J Roentgenol. 2015;205(3):564-571. doi:10.2214/AJR.14.13602 Google Scholar
[3]
3. Eldib DB, Moussa AS, Sebaey A. Evaluation of different MRI parameters in benign prostatic hyperplasia-induced bladder outlet obstruction. Egypt J Radiol Nucl Med. 2019;50(1):22. doi:10.1186/s43055-019-0030-y Google Scholar
[4]
4. Eldib DB, Moussa AS, Sebaey A. Evaluation of different MRI parameters in benign prostatic hyperplasia-induced bladder outlet obstruction. Egypt J Radiol Nucl Med. 2019;50(1):22. doi:10.1186/s43055-019-0030-y Google Scholar
[5]
5. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. Curr Urol. 2018;11(3):117-125. doi:10.1159/000447205 Google Scholar
[6]
6. Barry MJ, Fowler FJ, O’Leary MP, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol. Published online November 1992. doi:10.1016/S0022-5347(17)36966-5 Google Scholar
[7]
7. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-1109. doi:10.1016/j.eururo.2014.12.038 Google Scholar
[8]
8. Mochtar CA, Kiemeney L a. LM, van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2003;44(6):695-700. doi:10.1016/s0302-2838(03)00384-1 Google Scholar
[9]
9. Anyimba SK, Amu OC, Nnabugwu II, Okoh AD, Nwachukwu CD, Iwenofu CA. Prevalence and Distribution of Postvoid Residual Urine Volume in a Hospital-Based Sample of Men with Symptomatic Benign Prostatic Hyperplasia. Niger J Clin Pract. 2023;26(12):1839-1843. doi:10.4103/njcp.njcp_339_23 Google Scholar
[10]
10. Ko YH, Chae JY, Jeong SM, et al. Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events. Int Neurourol J. 2010;14(4):238-244. doi:10.5213/inj.2010.14.4.238 Google Scholar
[11]
11. Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic enlargement. Urology. 2007;70(6):1096-1099. doi:10.1016/j.urology.2007.08.008 Google Scholar
[12]
12. Gandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Curr Urol. 2018;12(1):6-12. doi:10.1159/000447224 Google Scholar
[13]
13. Wasserman NF, Spilseth B, Golzarian J, Metzger GJ. Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies. AJR Am J Roentgenol. 2015;205(3):564-571. doi:10.2214/AJR.14.13602 Google Scholar
[14]
14. Boschheidgen M, Al-Monajjed R, Minko P, et al. Influence of benign prostatic hyperplasia patterns detected with MRI on the clinical outcome after prostatic artery embolization. CVIR Endovasc. 2023;6:9. doi:10.1186/s42155-023-00357-y Google Scholar
[15]
15. Keqin Z, Zhishun X, Jing Z, Haixin W, Dongqing Z, Benkang S. Clinical Significance of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Enlargement. Urology. 2007;70(6):1096-1099. doi:10.1016/j.urology.2007.08.008 Google Scholar